Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Imiquimod + zalifrelimab by UroGen Pharma for Prostate Cancer: Likelihood of Approval
Imiquimod + zalifrelimab is under clinical development by UroGen Pharma and currently in Phase I for Prostate Cancer. According to...
Data Insights
Imiquimod + zalifrelimab by UroGen Pharma for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval
Imiquimod + zalifrelimab is under clinical development by UroGen Pharma and currently in Phase I for Non Muscle Invasive Bladder...